Searched for
BIOSIMILARS AND COMPLEX GENERICS
Pharma sector revenue to grow 11-13 pc in FY27 on strong exports, domestic demand: CrisilIndia's pharmaceutical sector is projected to grow at 11-13 percent this fiscal year due to export increases. The domestic market is also e...- Zydus gearing up for next phase of growth, eyeing new areas: Sharvil Patel, MD"From 2030 and beyond, we will see strong earnings from pure discovery-led business, which is our central business, our oncology business a...
- MF Tracker: HDFC Pharma & Healthcare Fund tops equity MFs at 25% in 1 year. Should investors chase the rally?HDFC Pharma and Healthcare Fund recorded an impressive 25% return in the last year, surpassing its category average across various time fra...
- Short-term headwind? Yes. But the structure stays intact: 5 large-cap stocks with upside potential of up to 19%Wise men on the street will tell you it is foolish to try and time the market. And attempting to do so in the midst of a raging war is prob...
- Biocon shares rise 3% after Rs 638-crore block deal; Active Pine likely sellerBiocon shares rose after a block deal involving around 1.65 crore shares. Investor Active Pine was reportedly looking to sell up to 1.66 cr...
- Biocon shares: Active Pine may divest up to 1% equity worth Rs 638 crore via block dealActive Pine is likely to sell up to 1.66 crore Biocon shares, worth Rs 638 crore, through a block deal at Rs 385 per share. The development...
- When volatility rises, will you panic or buy? Depends on the watchlist you build now: 5 large-cap stocks with upside potential of up to 32%Another worry has emerged for the markets, and it will drive the narrative in the short term. As usual, it comes from the US. The US Fed ha...
- Drug formulations & biologicals keep India's pharma exports healthy in Q1During the first quarter of fiscal 2027, India's pharmaceutical exports soared to $8.10 billion, showcasing remarkable strength in drug for...
- Picking the right pharma stock is getting harder; so pick a portfolio: 20 stocks with -23% to +22% downside to upside potentialFor Indian pharma, the regulatory risk is still real. A US FDA inspection can still cause trouble. A plant making an important product or g...
- Tariff on generic drugs: Loud announcement, little consequence? 7 pharma stocks with upside potential of up to 31%The threat of a US tariff on Indian pharma is no longer a vague fear; or at least that is what President Trump wants us to believe. There i...
- Where to invest within the pharma theme? Industry expert Kewal Handa answersIndian per capita income increase will lead to increased spending on healthcare and medicines, including both generic and non-generic produ...
- A growth formula for generics, biosimilarsUnder the scheme, financial incentives will be given to eligible manufacturers of complex generics and biopharmaceuticals on their sales ov...
- Understanding the biosimilars opportunity for Indian pharmaBiosimilars to biologic drugs are what generics are to chemical drugs.
- Lupin to launch nearly 30 products in US market in FY18The drug firm is banking on the introduction of complex generics and biosimilars in the US to maintain its top five position in the market.
- Complex generics, biosimilars & specialty to be growth drivers: LupinWhile sustaining and growing its presence in the generics segment, Lupin is planning to invest heavily in developing high barrier products ...
- USFDA is trying to approve biosimilars and evolve the process concurrently: Kiran Mazumdar Shaw, Biocon"Our clinical data package has been approved by ODAC recently, and the GMP part of the regulatory process has already seen us-- provide a s...
- India offers better opportunity for biosimilar drugs: Cadila Healthcare founder Pankaj PatelBiosimilars are follow-on versions of biologic drugs and far more complex and more difficult to copy than generic drugs because of the stru...
- Make in India: Can India be a hub for the $200 billion worth biosimilars opportunityThe Indian biogenerics industry is poised to exploit the opportunity they did in the case of generics, although it has no clear advantage a...
- Biocon-Mylan partnership has a potential of $33 billion from biosimilar drugsTwo years after announcing a JV with Mylan, Biocon has revealed the potential of its drugs under the biologics deal with Mylan.
- DRL to launch biosimilar drugs in Europe by '10India's largest drug maker, Dr Reddy’s Laboratories, is planning to introduce its first biosimilar drug by 2010 in Europe, a senior company...
Load More
